Interestingly, inhibiting ART1 expression by genetic ablation or blocking ART1’s enzymatic activity using a humanized monoclonal activity triggered a robust antitumor immune response, which resulted in a significant reduction in tumor burden [367,368,369,370]. Here, ART1 is linked to neoplasm.